Get the Stockscreener App
61.97
0.67%
-0.42
Pre-market:
61.84
-0.13
-0.21%
Rhythm Pharmaceuticals Inc stock is traded at $61.97, with a volume of 358.25K.
It is down -0.67% in the last 24 hours and up +3.40% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$62.39
Open:
$61.75
24h Volume:
358.25K
Relative Volume:
0.53
Market Cap:
$4.29B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-22.05
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
-8.02%
1M Performance:
+3.40%
6M Performance:
+9.10%
1Y Performance:
+50.56%
1-Day Range:
$60.80
$62.61
1-Week Range:
$60.80
$67.27
52-Week Range:
$39.46
$69.89
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
61.97 | 4.29B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A. - Defense World
(RYTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $76.62 Average Target Price from Brokerages - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Rhumbline Advisers - Defense World
Rhythm Pharma stock soars to all-time high of $69.7 By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals at Goldman Sachs Conference: Strategic Focus on Rare Diseases - Investing.com Nigeria
Rhythm Pharma stock soars to all-time high of $69.7 - Investing.com Australia
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism - MSN
Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target - Yahoo Finance
Jefferies maintains buy rating on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Citizens JMP maintains $84 target on Rhythm Pharmaceuticals stock By Investing.com - Investing.com UK
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Jefferies Conference: Strategic Pipeline Insights - Investing.com
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Stifel Nicolaus Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World
Rhythm Pharmaceuticals (RYTM) Target Price Raised by Stifel Anal - GuruFocus
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know - Benzinga
Rhythm Pharmaceuticals (RYTM) Stock Jumps Nearly 6%: What's Driving the Upbeat Tempo? - Daily Chhattisgarh News
Stifel raises Rhythm Pharma stock target to $94, keeps Buy rating - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | - GuruFocus
Rhythm Pharmaceuticals (RYTM) Target Price Boosted by Analyst | RYTM Stock News - GuruFocus
Ameriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
POMC Deficiency Obesity Market on Track for Major Expansion - openPR.com
(RYTM) Investment Analysis - news.stocktradersdaily.com
Deutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Gotham Asset Management LLC Sells 2,685 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $75.38 Consensus Price Target from Analysts - Defense World
Rhythm Pharmaceuticals Announces New Data Presentations on Patie - GuruFocus
(RYTM) On The My Stocks Page - news.stocktradersdaily.com
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | - GuruFocus
RYTM Shows Positive Results in Hypothalamic Obesity Treatment | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program - GlobeNewswire
New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan
Raymond James Financial Inc. Buys New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
HC Wainwright Has Negative Estimate for RYTM Q2 Earnings - Defense World
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 6.6% on Disappointing Earnings - Defense World
Needham & Company LLC Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $72.00 - Defense World
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada
RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com
Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases - marketscreener.com
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):